Thursday, July 9, 2026

pharma · Minimal Residual Disease · Pancreatic Ductal Adenocarcinoma · ELTX

Elicio Therapeutics

Elicio Therapeutics clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Boston, USA HQ
47 Employees
Public company Type
ELTX · NYSE Ticker
Company details
Status
Public
HQ
Boston, USA
Employees
47
Programs
2
Drugs
0
Patents
4
Intelligence · Clinical Programs

Elicio Therapeutics projects

1 ClinicalTrials.gov programs sponsored by Elicio Therapeutics.

Elicio Therapeutics has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ELI-002 2P

    Elicio Therapeutics

    Minimal Residual Disease

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Elicio Therapeutics have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.